^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    irinotecan

    i
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    Apply
    A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)
    Phase 1
    Incyte Corporation
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/04/2024
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    KRAS
    |
    Erbitux (cetuximab) • irinotecan • Zynyz (retifanlimab-dlwr)
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) (NCT04607421)
    Phase 3
    Pfizer
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/21/2020
    Primary completion :
    01/06/2025
    Completion :
    12/24/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Zirabev (bevacizumab-bvzr) • Khapzory (levoleucovorin) • levoleucovorin calcium
    Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) (NCT02980510)
    Phase 2
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/01/2016
    Primary completion :
    12/01/2025
    Completion :
    01/01/2026
    KRAS • RAS
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (NCT00045201)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/13/2002
    Primary completion :
    09/13/2013
    Completion :
    08/22/2025
    EGFR • UGT1A1
    |
    UGT1A1*1*1
    |
    erlotinib • irinotecan
    Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer (NCT06833866)
    Phase 1
    The Methodist Hospital Research Institute
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/04/2024
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    CD8 • CD4
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    04/19/2024
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    ALK • TERT • MYCN
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors (IMM1104-101) (NCT05585320)
    Phase 1/2
    Immuneering Corporation
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/31/2022
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    KRAS • HRAS • APC
    |
    KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • IMM-1-104
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (NCT06011772)
    Phase 1
    Roswell Park Cancer Institute
    Suspended
    Last update posted :
    02/19/2025
    Initiation :
    12/04/2023
    Primary completion :
    12/04/2025
    Completion :
    12/04/2026
    KRAS • BRAF • RAS
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06818812)
    Phase 1
    Incyte Corporation
    Not yet recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/10/2025
    Primary completion :
    03/27/2027
    Completion :
    03/27/2027
    KRAS
    |
    Erbitux (cetuximab) • irinotecan
    Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (NCT03290937)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    12/27/2017
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    MSI
    |
    MSI-H/dMMR • RAS mutation
    |
    Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (ST316-101) (NCT05848739)
    Phase 1
    Sapience Therapeutics
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    PD-L1 • MSI • BRCA
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316
    PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) (NCT04787341)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/15/2020
    Primary completion :
    06/15/2025
    Completion :
    12/15/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Avastin (bevacizumab) • Vectibix (panitumumab) • Stivarga (regorafenib) • oxaliplatin • irinotecan
    VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors (NCT04796012)
    Phase 1/2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/18/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    PD-L1
    |
    Tecentriq (atezolizumab) • temozolomide • irinotecan • vincristine
    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT (NCT04322318)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/19/2020
    Primary completion :
    07/01/2027
    Completion :
    07/01/2027
    TP53
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan
    Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (NCT03533582)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/24/2018
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    SMARCB1 • AFP
    |
    AFP elevation
    |
    cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical
    Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (NCT03794349)
    Phase 2
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/08/2019
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    IFNG • IL6 • CD276 • TNFA
    |
    temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (CodeBreak101) (NCT04185883)
    Phase 1
    Amgen
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/17/2019
    Primary completion :
    04/29/2026
    Completion :
    03/13/2028
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • zeluvalimab (AMG 404)
    Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma (NCT06620302)
    Phase 1/2
    Children's Oncology Group
    Not yet recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/20/2025
    Primary completion :
    12/30/2031
    Completion :
    12/30/2031
    BCL2 • DNAJB1 • PRKACA
    |
    irinotecan • DT2216
    Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse) (NCT06640166)
    Phase 2
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    06/03/2024
    Primary completion :
    12/31/2025
    Completion :
    06/30/2026
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium
    Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (NCT04793958)
    Phase 3
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    06/24/2021
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Krazati (adagrasib) • leucovorin calcium
    A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2) (NCT06662786)
    Phase 3
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/18/2024
    Primary completion :
    12/15/2028
    Completion :
    12/15/2032
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium
    Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer (NCT05278728)
    Phase 1/2
    Biotech Pharmaceutical Co., Ltd.
    Completed
    Last update posted :
    02/07/2025
    Initiation :
    07/01/2009
    Primary completion :
    08/01/2013
    Completion :
    12/01/2013
    KRAS • RAS
    |
    irinotecan • TheraCIM (nimotuzumab)
    TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (TTX-080-001) (NCT04485013)
    Phase 1
    Tizona Therapeutics, Inc
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/14/2020
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    BRAF
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
    Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (NCT02769962)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    05/09/2016
    Primary completion :
    07/01/2025
    Completion :
    12/31/2027
    BRCA
    |
    Lynparza (olaparib) • irinotecan
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (S1513) (NCT02890355)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/01/2016
    Primary completion :
    05/01/2019
    Completion :
    03/05/2025
    BRCA1 • BRCA2 • HRD • CEACAM5
    |
    HRD
    |
    5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical
    Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases (CAIRO5) (NCT02162563)
    Phase 3
    Dutch Colorectal Cancer Group
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    07/01/2014
    Primary completion :
    07/01/2022
    Completion :
    01/01/2025
    BRAF • RAS
    |
    BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer (NCT02138617)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    05/01/2014
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    UGT1A1
    |
    UGT1A1*1*1
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)
    A Study of ASP3082 in Adults With Advanced Solid Tumors (3082-CL-0101) (NCT05382559)
    Phase 1
    Astellas Pharma Inc
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/08/2022
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • ASP3082
    Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (NCT01814501)
    Phase 2
    John Hays
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    02/01/2013
    Primary completion :
    08/06/2018
    Completion :
    08/06/2018
    KRAS
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium
    Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (ARST1431) (NCT02567435)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/01/2016
    Primary completion :
    06/30/2023
    Completion :
    10/16/2025
    FOXO1 • PAX3 • PAX7
    |
    cyclophosphamide • irinotecan • Torisel (temsirolimus) • vincristine • vinorelbine tartrate • dactinomycin
    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NCT05174169)
    Phase 2/3
    NRG Oncology
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/10/2022
    Primary completion :
    03/10/2029
    Completion :
    03/10/2030
    MSI
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (NCT00980460)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    09/14/2009
    Primary completion :
    06/30/2020
    Completion :
    03/05/2025
    AFP
    |
    AFP elevation
    |
    cisplatin • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • Torisel (temsirolimus) • vincristine • fluorouracil topical • dexrazoxane
    A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3) (NCT06750094)
    Phase 3
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/12/2024
    Primary completion :
    12/15/2027
    Completion :
    04/13/2029
    BRAF
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium
    Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (NCT05482893)
    Phase 1/2
    Phanes Therapeutics
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/15/2023
    Primary completion :
    12/01/2027
    Completion :
    04/01/2028
    CLDN18
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • spevatamig (PT886)
    Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa) (NCT01878422)
    Phase 3
    Istituto Scientifico Romagnolo per lo Studio e ...
    Completed
    Last update posted :
    01/31/2025
    Initiation :
    11/01/2007
    Primary completion :
    03/01/2014
    Completion :
    06/11/2016
    KRAS
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (MCLA-158-CL01) (NCT03526835)
    Phase 1/2
    Merus N.V.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/02/2018
    Primary completion :
    11/01/2025
    Completion :
    11/01/2027
    EGFR
    |
    EGFR amplification
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • petosemtamab (MCLA-158)
    PhII ICb With/Without Erbitux in MBC Pts (CA225200) (NCT00248287)
    Phase 2
    US Oncology Research
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    07/28/2005
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    EGFR • HER-2 • PGR
    |
    HER-2 negative
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • irinotecan
    A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (NCT06607185)
    Phase 1
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    10/21/2024
    Primary completion :
    01/01/2030
    Completion :
    01/01/2030
    KRAS
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (MOONRAY-01) (NCT06586515)
    Phase 1
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    09/12/2024
    Primary completion :
    03/01/2029
    Completion :
    03/01/2029
    KRAS
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/revert Resistance in Colorectal Cancer (VICTORIA) (NCT06714357)
    Phase 2
    National Cancer Institute, Naples
    Not yet recruiting
    Last update posted :
    01/28/2025
    Initiation :
    01/01/2025
    Primary completion :
    12/20/2026
    Completion :
    06/20/2027
    BRAF
    |
    Vectibix (panitumumab) • irinotecan